Program
pralurbactam
Also written as “Meropenem and Pralurbactam”, “FL058” and “Meropenem- FL058”.
Its studies are mostly in Pneumonia, Bacterial · Sepsis · Intraabdominal Infections · Pyelonephritis, led by Qilu Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Qilu Pharmaceutical | 73 open or running | phase 3since Sep 26, 2024 | Sep 8, 2021 | Dec 2026phase 3 · NCT07089186 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 8, 2021First studies: 3 phase 1 studies in HealthyFirst studyNCT05058118, NCT05058105, NCT05055687
- Sep 18, 2021Phase 2 study in Complicated Urinary Tract InfectionNCT05060419 · 150 enrolled
- Sep 26, 2024Phase 3 study in Intraabdominal InfectionsNCT06633718 · 786 planned · China
- Jun 25, 2025Phase 3 study in SepsisNCT07089186 · 80 planned · China
- Dec 26, 2025Phase 3 study in Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial PneumoniaNCT07327619 · 420 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in SepsisNCT07089186
- May 30, 2027Primary completion: phase 3 study in Intraabdominal InfectionsNCT06633718
- Jun 2028Primary completion: phase 3 study in Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial PneumoniaNCT07327619
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 7 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07327619Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia · China | 3 | Recruiting | Jun 2028 | 420 |
| NCT07089186Sepsis · China | 3 | Recruiting | Dec 2026 | 80 |
| NCT06633718Intraabdominal Infections · China | 3 | Not yet recruiting | May 30, 2027 | 786 |
| NCT05060419Complicated Urinary Tract Infection | 2 | UNKNOWN | Apr 29, 2022 | 150 |
| NCT05058118Healthy · China | 1 | Completed | Jun 3, 2020 | 54 |
| NCT05058105Healthy · China | 1 | Completed | Feb 24, 2021 | 40 |
| NCT05055687Healthy · China | 1 | Completed | Jul 27, 2020 | 20 |
How it is read
Names in the registry
- “Meropenem and Pralurbactam”, 3 entries
- “FL058”, 3 entries
- “Meropenem- FL058”, 1 entry
- “FL058 500mg and Meropenem 1000mg( IV 120min)”, 1 entry
- “FL058 1000mg( IV 120min)”, 1 entry
Codes read as this program: FL058.
Conditions, from the studies’ own filings
- Pneumonia, Bacterial, 1 study
- Sepsis, 1 study
- Intraabdominal Infections, 1 study
- Pyelonephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.